Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 13/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20027818 | 1.00 | CAPN1 (0.49) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL20028561 | 0.94 | CAPN1 (0.54) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL21854059 | 0.94 | CAPN1 (0.54) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL20027651 | 0.94 | CAPN1 (0.50) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL20027745 | 0.94 | CAPN1 (0.50) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL20027957 | 0.94 | CAPN1 (0.52) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL21854211 | 0.91 | CAPN1 (0.49) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL20027829 | 0.91 | CAPN1 (0.49) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL21854108 | 0.91 | CAPN1 (0.52) | CAPN1F10F2PRSS1PRSS2 | |
| SCHEMBL20027684 | 0.91 | CAPN1 (0.52) | CAPN1F10F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885F10 4552/4885F2 4865/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885F10 4552/4885F2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.